Congressional spending plan: What’s in it for healthcare, and what isn’t
Chief Healthcare Executive December 21, 2024
Safety Stands Out in Arcellx Cell Therapy’s ASH Data, But Don’t Overlook Manufacturing Advantages
MedCity News December 10, 2024
Arcellx’s cell therapy for multiple myeloma has shown no signs of the parkinsonism complication observed in clinical testing of Carvykti, a rival product from partners Johnson & Johnon and Legend Biotech. Arcellx is developing its CAR T-treatment under a partnership with Gilead Sciences.
Cell therapy developer Arcellx contends its lead program could be a safer alternative to currently available CAR T-treatments for multiple myeloma, noting that its previously reported preliminary data show the absence of worrisome neurological complications some fear could be associated with the broader therapeutic class. More detailed data presented at the American Society of Hematology annual meeting build on the safety profile of the Gilead Sciences-partnered Arcellx therapy, which some analysts now say has the potential to...
Today's Sponsors
Today's Sponsor